PREDIABETES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Prediabetes Market Size and Forecast – 2025 - 2032

The Global Prediabetes Market is estimated to be valued at USD 8.81 Bn in 2025 and is expected to reach USD 15.10 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032. This significant growth is driven by the rising prevalence of prediabetes worldwide, increased awareness about early diagnosis, and advancements in diagnostic technologies. The expanding healthcare infrastructure and growing focus on preventive healthcare are also key factors contributing to market expansion during this period.

Key Takeaways of the global prediabetes market

• Metformin remains the leading treatment in the global prediabetes market, holding a 60. 1% share in 2025.
• In terms of gender, males represent the majority of the market, accounting for 65. 3% in 2025.
• The adult age group dominates the market, with a 75. 3% share in 2025.
• North America is expected to lead the market, holding a share of 37.3% in 2025.
• Asia Pacific is anticipated to be the fastest-growing region, with a market share of 25.3% in 2025.

Market Overview

Current trends in the global prediabetes market include a shift towards personalized medicine and digital health monitoring tools, enhancing early detection and management of the condition. The integration of AI and machine learning in diagnostic procedures is improving accuracy and patient outcomes. Additionally, there is a growing emphasis on lifestyle interventions and pharmacological treatments aimed at delaying or preventing the progression of prediabetes to type 2 diabetes. These trends are fostering innovation and competitive dynamics within the market, supporting sustained growth.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Prediabetes Market Insights, By Treatment - In terms of By Treatment & Management, Metformin contributes the highest share of the market owing to its proven clinical efficacy and well-established role in prediabetes management

Metformin stands out as the most dominant treatment option within the global prediabetes market with an estimated share of 60.1% in 2025, due to its long-standing presence and extensive clinical validation in delaying the onset of type 2 diabetes. One of the primary factors driving its market share is the strong evidence-base from numerous randomized controlled trials demonstrating its ability to improve insulin sensitivity and lower glucose production in the liver, thereby effectively managing blood sugar levels in prediabetic patients. Medical guidelines from various international diabetes associations continue to recommend Metformin as a first-line pharmacological intervention, especially for individuals at high risk or those with impaired glucose tolerance.

The medication’s cost-effectiveness compared to other emerging therapies also reinforces its preference among healthcare providers and patients. Metformin’s generic availability makes it accessible in both developed and developing regions, contributing to its widespread adoption. Additionally, its favorable safety profile, with minimal severe side effects, encourages long-term use which is essential for chronic conditions like prediabetes.

For example, in July 2024, according to John Wiley & Sons, Inc. research study, commonly known as Wiley, an American multinational publishing company, Metformin, widely used as a foundational therapy for type 2 diabetes, also has several emerging clinical uses, including in polycystic ovarian syndrome, gestational diabetes, prediabetes prevention, and as an adjunct in type 1 diabetes. Its benefits may stem from effects on weight loss and insulin sensitivity, but it has multiple mechanisms of action. While metformin has been in use for nearly 70 years, many of these indications are based on older trials, with some considered off-label in various countries.

Prediabetes Market Insights, By Gender

Male Segment Leads Market Share Driven by Higher Prediabetes Prevalence and Increased Health Awareness

Within the gender segmentation of the global prediabetes market, males account for the majority share with an estimated 65.3% in 2025, a trend largely influenced by a combination of biological, behavioral, and socio-cultural factors. Epidemiological studies frequently indicate a higher prevalence of impaired glucose regulation and insulin resistance in men compared to women, attributable in part to differences in fat distribution, hormonal profiles, and lifestyle patterns. Men tend to accumulate more visceral fat, which is strongly correlated   with metabolic dysfunction and heightened prediabetes risk.

Behavioral aspects also contribute to this segment’s prominence. Men are generally more prone to risk factors such as unhealthy dietary habits, sedentary lifestyles, smoking, and excessive alcohol consumption, all of which exacerbate predisposition to elevated blood glucose levels. These risk factors, when combined with genetic susceptibility, increase the likelihood of prediabetes, thereby driving demand for diagnostic interventions and therapeutic products targeted toward the male population.

In January 2024, a recent population-based cohort study by National Library of Medicine, involving 11,014 subjects aged 6-80 years revealed significant sex and gender differences in prediabetes and diabetes comorbidities. Men had a higher prevalence of prediabetes (23.6%) and diabetes (7.3%) than women (17.1% and 3.7%, respectively). Men were more likely to experience cardiovascular issues, while women had higher rates of arrhythmia, osteoporosis, and depression. In Shenzhen, China, another study found that males had a higher prevalence of prediabetes than females, with 9.80% of participants identified using combined FPG-or-HbA1c criteria.

Prediabetes Market Insights, By Age Group - Adult Age Group Dominates Owing to Rising Lifestyle-Related Risk Factors and Increased Diagnosis Rates

The adult segment leads the global prediabetes market primarily, with an estimated share of 75.3% in 2025, due to the higher incidence of metabolic disturbances in this age group fueled by contemporary lifestyle trends. Adults are more susceptible to risk factors such as sedentary work environments, poor diet characterized by high-calorie and processed foods, chronic stress, and obesity, all of which contribute heavily to the development of insulin resistance and impaired glucose tolerance. The broader demographic transition with longer life expectancies has also increased the pool of adults at risk, further enlarging this segment’s market share.

Increased public health initiatives and corporate wellness programs targeting adults have promoted widespread screening campaigns, resulting in early diagnosis of prediabetes in this population subset. This heightened detection rate has translated to greater adoption of treatment and management options such as Metformin, glucose monitoring devices, and digital health platforms designed to facilitate behavior modification and continuous health tracking.

Moreover, adults tend to have more autonomy over healthcare decisions and financial resources, facilitating better access to prescribed treatments and modern management technologies. The rising penetration of smartphones and wearable devices within the adult population accelerates adoption of digital health solutions that empower patients through data-driven insights and real-time glucose monitoring, supporting more effective disease management.

Regional Insights

To learn more about this report, Download Free Sample

North America Prediabetes Market Analysis and Trends

North America’s dominance in the global prediabetes market, with an estimated share of 37.3% in 2025, stems from a highly developed healthcare infrastructure, widespread awareness of diabetes and prediabetes conditions, and strong government initiatives aimed at early diagnosis and preventive care. For example, Health Canada promotes early detection and prevention of diabetes through the Canadian Diabetes Strategy, focusing on reducing the incidence of diabetes by promoting healthy eating, physical activity, and education on prediabetes management. Moreover, the Affordable Care Act (ACA) Coverage of Diabetes Screening ensures that preventive services, including screenings for prediabetes and diabetes, are covered without cost-sharing, making early diagnosis more accessible to the public. The United States, in particular, benefits from extensive investment in medical research and advanced diagnostic technologies. Additionally, the presence of major pharmaceutical and biotechnology companies such as Medtronic, Abbott Laboratories, and Eli Lilly ensures a robust product pipeline and innovative treatment solutions.

Asia Pacific Prediabetes Market Analysis and Trends

The Asia Pacific exhibits the fastest growth in the prediabetes market with an estimated share of 25.3% in 2025, driven by rapid urbanization, increasing prevalence of sedentary lifestyles, and rising disposable incomes across countries like India and China. Governments in this region are actively promoting awareness campaigns and preventive healthcare programs to tackle the burgeoning diabetes epidemic.

In May 2025, Alpro Pharmacy, a leading healthcare provider in Malaysia, launched the ASAP Programme (Alpro Stand Against Prediabetes) to address the growing risk of prediabetes, affecting 1 in 4 Malaysians. This nationwide health campaign, running from April to June 2025, aims to raise awareness, encourage early screening, and offer professional care to help individuals reverse prediabetes. Alpro is offering 10,000 free HbA1c tests at over 300 locations across Malaysia. The program targets high-risk individuals, including those with a family history of diabetes, and promotes early detection, pharmacist-led counseling, and lifestyle changes to prevent the progression to Type 2 diabetes.

The market ecosystem benefits from expanding healthcare infrastructure, rising health insurance penetration, and growing public-private partnerships. Countries such as India have seen an influx of both global and local players like Dr. Reddy’s Laboratories and Sun Pharmaceutical Industries, which contribute affordable diagnostics and therapeutics targeting prediabetic populations.

Prediabetes Market Outlook for Key Countries

U.S. Prediabetes Market

The U.S.' market is characterized by cutting-edge technological advancements and extensive clinical research focused on prediabetes detection and management. Companies such as Abbott Laboratories provide innovative glucose monitoring systems helping improve patient outcomes. Government initiatives like the National Diabetes Prevention Program enhance awareness and screening efforts. Collaboration between healthcare providers, insurers, and pharmaceutical firms ensures comprehensive patient engagement and follow-through, maintaining the country’s leadership position.

For example, in August 2024, Medtronic, a global healthcare technology leader, received USFDA approval for its Simplera continuous glucose monitor (CGM), marking a significant expansion in its CGM offerings. It enables better management of prediabetes and early intervention, supporting lifestyle changes to prevent the progression to type 2 diabetes.

Germany Prediabetes Market

Germany’s prediabetes market thrives on a strong healthcare system emphasizing preventive care and early intervention. The country’s well-established reimbursement policies encourage the adoption of diagnostic and therapeutic tools. Major players like Bayer AG and Siemens Healthineers contribute significantly through their advanced diagnostic equipment and novel pharmaceutical solutions. Public campaigns supported by statutory health insurance providers further promote lifestyle changes essential for prediabetes management.

For example, Bayer AG plays a crucial role in the prediabetes market by offering advanced blood glucose monitoring systems and oral medications to help manage blood sugar levels. Their products aid in the early detection of prediabetes and help prevent its progression to type 2 diabetes, making them integral to early intervention strategies also Siemens Healthineers contributes significantly to the prediabetes market with its range of diagnostic equipment, including blood glucose monitors and laboratory diagnostics.

China Prediabetes Market

China continues to lead in fast adoption of advanced medical technologies and infrastructure expansion, which drives the prediabetes market. The Chinese government prioritizes chronic disease management within its public health agenda, fostering innovation and market penetration. Companies like Sino Biopharmaceutical and international firms including Johnson & Johnson collaborate in developing accessible, high-quality diagnostic solutions. Increasing health insurance coverage and urban centers equipped with modern healthcare facilities complement market expansion.

One key initiative in China's prediabetes market is the "Healthy China 2030" plan, which focuses on improving overall health and addressing chronic diseases, including prediabetes and diabetes. This national initiative emphasizes the expansion of healthcare infrastructure, increased access to healthcare services, and the adoption of advanced medical technologies. The government encourages innovation in diagnostic tools, such as glucose monitoring systems, and supports the development of preventive care programs to manage prediabetes effectively.

India Prediabetes Market Analysis and Trends

The India prediabetes market is estimated to be valued at USD 420.3 Mn in 2025 and is expected to reach USD 835.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.3% from 2025 to 2032.

India's prediabetes market is experiencing dynamic growth, driven by a rising prevalence of diabetes and increasing healthcare access. The government's focus on noncommunicable diseases (NCDs) and health policies supports the market's expansion, with local companies like Dr. Reddy’s Laboratories playing a pivotal role by providing cost-effective medications and diagnostic kits. Moreover, the growing adoption of telemedicine platforms and government-supported screening programs helps improve early diagnosis in rural and underserved populations, ensuring broader access to prediabetes management.

For instance, in April 2025, Ambrosia, a global leader in real-time health monitoring, launched India's first 24x7 real-time glucose and stress monitoring service. This innovative service combines advanced wearable sensors, AI-driven analytics, and remote monitoring to provide continuous health insights. It addresses the gap left by traditional glucose monitoring, which relies on intermittent testing, by offering real-time data for individuals with diabetes, prediabetes and stress-related disorders.

Epidemiology of Prediabetes in India

• The epidemiology of prediabetes in India reveals a growing public health challenge, according to data published in Diabetes Research and Clinical Practice journal by Elsevier B.V with 22.25% of adults affected by prediabetes, as indicated by recent studies. The prevalence of prediabetes is influenced by several factors, including age, socioeconomic status, urbanization, and lifestyle choices. Urban areas report higher rates of both prediabetes and diabetes compared to rural regions, largely due to sedentary lifestyles, high-calorie diets, and lower physical activity levels. The National Family Health Survey and other epidemiological studies have highlighted regional disparities, with states like Odisha showing particularly high rates of prediabetes, while Jammu & Kashmir has lower rates.
• In addition to lifestyle factors, genetic predisposition, dietary patterns, and socioeconomic status play a critical role in the development of prediabetes in India. Data from large-scale studies like the HbA1c-based epidemiological study shown a marked increase in prevalence among middle-aged adults, especially those with higher body mass index (BMI) and obesity. The lack of early diagnosis and the absence of routine screening in many parts of the country contribute to the growing number of undiagnosed individuals, leading to a significant burden on the healthcare system. The country’s rapid urbanization, coupled with poor awareness and healthcare access in rural areas, further exacerbates the problem. Effective public health campaigns, screening programs, and lifestyle interventions are urgently needed to mitigate the impact of prediabetes and prevent its progression to type 2 diabetes.

End User Feedback and Unmet Needs in the Global Prediabetes Market

• End user feedback in the global prediabetes market reveals a mix of satisfaction and ongoing concerns related to product performance, accessibility, and integration. On the positive side, many users express high satisfaction with the ease of use and real-time monitoring capabilities of continuous glucose monitoring (CGM) systems.
• For instance, Medtronic's Simplera CGM has received commendations for its compact size, making it a more comfortable option for individuals managing prediabetes. Users appreciate its integration with the InPen smart insulin pen, which simplifies insulin administration and improves overall diabetes management.
• These features highlight a successful convergence of technology and user-centric design, contributing to better patient outcomes and enhanced user engagement. However, concerns about accessibility persist, particularly in regions with limited healthcare infrastructure. For example, while CGMs are highly effective, the cost barrier remains significant, with many individuals in low-income areas unable to afford advanced monitoring systems.
• The unmet needs in the prediabetes market are centered on affordability, technology gaps, and customization of existing products. Despite the advances in CGM and insulin monitoring systems, the high cost of devices and lack of affordable healthcare solutions for low-income populations limit access to crucial preventive care. Furthermore, many users report challenges related to the lack of tailored solutions that account for individualized health conditions, particularly for those with coexisting chronic conditions.
• Addressing these gaps could drive growth opportunities by expanding market accessibility and improving customer retention through more affordable, customizable, and adaptable solutions. Additionally, overcoming technological limitations and increasing support services would create innovation-driven opportunities, fostering stronger engagement from both consumers and healthcare providers, and ensuring more people benefit from early intervention strategies.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In June 2024, Abbott, a global healthcare leader, received the U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems: Lingo and Libre Rio. Lingo is designed for consumers looking to improve their health and wellness by tracking glucose levels and offering personalized coaching for healthier lifestyle choices. It continuously streams data to a smartphone app, helping users manage food, exercise, and stress. Libre Rio is aimed at adults with Type 2 diabetes who do not require insulin, offering an over-the-counter CGM option to manage glucose levels through lifestyle changes.
• In August 2024, Eli Lilly and Company announced positive results from the SURMOUNT-1 Phase 3 study, which evaluated tirzepatide (Zepbound and Mounjaro) for weight management and the prevention of Type 2 diabetes in adults with prediabetes and obesity or overweight. The study found that weekly tirzepatide injections reduced the risk of developing Type 2 diabetes by 94% compared to a placebo. Additionally, participants on the 15 mg dose of tirzepatide experienced an average 22.9% weight loss over the 176-week treatment period. These findings support the potential long-term benefits of tirzepatide in managing obesity and preventing diabetes.
• In November 2024, Redcliffe Labs, a leading healthcare technology company, has launched the Prediabetes Risk Checker on its Android app in celebration of World Diabetes Day. This tool is part of Redcliffe's "Beat the Sugar Trap" campaign aimed at tackling the growing prevalence of diabetes and prediabetes in India. By assessing users' lifestyle habits and genetic factors, the tool provides personalized risk assessments and actionable health insights. The initiative promotes early detection and preventive care, especially important as India has over 136 million individuals with prediabetes. Redcliffe Labs aims to empower users to take proactive steps towards managing their health with tailored recommendations, including lifestyle changes and diagnostic testing.
• In July 2023, Dexcom, a leading provider of continuous glucose monitoring (CGM) devices, announced the development of a novel wearable for managing Type 2 diabetes without the need for insulin. This innovative device, expected to launch in over a year, will feature a 15-day sensor and provide a cash-pay option for patients without insurance coverage. The device is designed to support decision-making related to exercise, food, and medication, offering valuable insights into how daily habits impact the condition. It aims to benefit Type 2 diabetes patients and prediabetic individuals, helping them manage their condition more effectively and make informed lifestyle choices.

Top Strategies Followed by Global Prediabetes Market Players

• Established market leaders predominantly invest heavily in research and development (R&D) to innovate high-performance products that address the evolving needs of prediabetic patients. By continuously enhancing the precision and user-friendliness of diagnostic tools and monitoring devices, these companies maintain their technological edge. Additionally, they form strategic partnerships and alliances with major industry players, original equipment manufacturers (OEMs), and healthcare providers to expand their product portfolios and gain access to new technologies. Such collaborations not only solidify their presence in mature markets but also facilitate the integration of solutions within broader healthcare ecosystems.

• Mid-level players in the prediabetes market adopt a differentiated approach that balances quality with cost-effectiveness, aiming to attract price-sensitive consumers primarily in developing markets or among lower-income demographics. These companies emphasize the development and marketing of affordable diagnostic kits, wearable sensors, and management platforms that deliver reliable performance without premium pricing. To enhance their competitive positioning, mid-level companies often engage in collaborations with technology providers, contract manufacturers, and regional distributors to boost production efficiency and expand market reach. Such partnerships enable these players to access innovative manufacturing techniques, reduce costs, and improve supply chain agility.

• Small-scale players typically carve out market niches by concentrating on specialized features or pioneering innovations that distinguish their offerings from those of larger competitors. These companies invest in cutting-edge technologies such as artificial intelligence-driven analytics, wearable IoT devices, or non-invasive glucose monitoring methods that appeal to tech-savvy and early-adopter segments. By targeting specific sub-segments of the market—such as remote patient monitoring or integration with wellness apps small players differentiate themselves while addressing unmet clinical or consumer needs.

Market Report Scope

Prediabetes Market Report Coverage

Prediabetes Market Dynamics

To learn more about this report, Download Free Sample

Prediabetes Market Driver - Increasing prevalence of obesity and sedentary lifestyles

The increasing prevalence of obesity and sedentary lifestyles across the globe is a significant driver propelling the growth of the prediabetes market. Modern urbanization and technological advancements have led to reduced physical activity levels, with more individuals leading sedentary lives due to desk-bound jobs, increased screen time, and the convenience of motorized transport. Coupled with this, unhealthy dietary habits characterized by high-calorie, processed foods have contributed substantially to the escalating rates of overweight and obesity. Excess body weight is a well-established risk factor for insulin resistance, which directly accelerates the transition from normal glucose regulation to prediabetic conditions. As a result, more individuals fall into the prediabetes category, creating a heightened need for early diagnosis, monitoring, and intervention strategies.

In May 2025, according to the data by the World Health Organisation (WHO), in 2022, 1 in 8 people globally were living with obesity, with adult obesity more than doubling since 1990. Over 2.5 billion adults were overweight, and 16% of adults were obese. Childhood obesity is also rising, with 390 million children aged 5–19 overweight and 35 million children under 5 affected. The causes are linked to unhealthy diets, lack of physical activity, and socio-environmental factors. Obesity is linked to serious health issues like heart disease and diabetes, contributing to 3.7 million deaths in 2021. Global economic costs of obesity could reach USD 3 trillion annually by 2030.

Prediabetes Market Opportunity: Expansion of Digital Health Platforms for Monitoring in the global prediabetes market

The rapid advancement and adoption of digital health platforms present a significant opportunity for growth in the global prediabetes market. These platforms, including mobile health apps, wearable devices, remote monitoring tools, and telemedicine services, offer innovative solutions for early detection, continuous monitoring, and personalized management of prediabetes. The integration of artificial intelligence (AI) and machine learning algorithms into these platforms enables more accurate risk assessments and real-time data analysis, empowering healthcare providers and patients to make informed decisions.

 Moreover, digital health platforms facilitate greater patient engagement and adherence to lifestyle modifications or treatment regimens through interactive features such as reminders, educational content, and virtual coaching. For example, Omada Health provides a digital health prediabetes program that helps individuals with prediabetes make lifestyle changes through remote coaching, personalized feedback, and digital tools. The platform incorporates AI and data analytics to track progress and offer tailored advice, supporting better outcomes in managing and preventing diabetes.

Analyst Opinion (Expert Opinion)

• The global prediabetes market is poised for significant growth, driven by the increasing prevalence of obesity, sedentary lifestyles, and rising awareness around diabetes prevention. Technological advancements in glucose monitoring devices and digital health platforms are enabling proactive management of prediabetes, while strategic partnerships between key players like Abbott Laboratories and Medtronic are expanding global outreach. Additionally, regulatory support for early detection and management of metabolic risks is fostering market growth. However, the market faces challenges such as high underdiagnosis rates, limited access to healthcare in rural areas, and affordability issues related to treatment and management solutions.
• Emerging opportunities lie in expanding digital health solutions and wearable devices, which allow individuals to monitor their health remotely. Notable industry events such as the American Diabetes Association (ADA) Annual Meeting and International Diabetes Federation Congress have played a significant role in advancing knowledge-sharing, policy formulation, and showcasing innovations. Moreover, government initiatives and global awareness campaigns, like those by the WHO and public-private partnerships, continue to create an enabling environment for market expansion. These collaborative efforts aim to reduce the rising burden of diabetes and prediabetes, especially in underserved regions.

Market Segmentation

•  Treatment & Management Insights (Revenue, USD Bn, 2020 - 2032)
  • Metformin
  • Digital Health and Wearables
  • Glucose Monitoring Devices (CGM, BGM)
  • Herbal Supplements 
  • Others (Probiotics and Gut Health Products, etc.)
•  Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
•  Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Pediatric
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Online
  • Offline
  • Specialty Pharmacies and Drugstores
  • Supermarkets or Hypermarkets
•  Weight Category Insights (Revenue, USD Bn, 2020 - 2032)
  • Overweight and Obese Individuals (Primary Target)
  • Normal Weight with Metabolic Risk (Underdiagnosed Segment)
•  End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Diagnostic Laboratories
  • Home Care Settings
  • Specialty Clinics
  • Health and Wellness Centers
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Bristol-Myers Squibb
  • Mylan Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceutical Industries
  • Sandoz (Novartis)
  • Glenmark
  • Dexcom
  • Abbott Laboratories
  • Medtronic
  • Ascensia Diabetes Care
  • Senseonics
  • Herbalife Nutrition
  • Nestlé Health Science
  • Danone

Sources

Primary Research Interviews

• Healthcare professionals specializing in endocrinology and diabetes care
• Public health experts and epidemiologists
• Patients diagnosed with prediabetes and type 2 diabetes
• Community health workers and outreach coordinators
• Dietitians and nutritionists involved in diabetes prevention programs

Government and International Databases

• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• National Institutes of Health (NIH)
• European Medicines Agency (EMA)
• U.S. Food and Drug Administration (FDA)
• National Health and Nutrition Examination Survey (NHANES)

Trade Publications

• Diabetes Care (American Diabetes Association)
• The Lancet Diabetes & Endocrinology
• Diabetologia
• Journal of Clinical Endocrinology & Metabolism
• Diabetes Research and Clinical Practice
• Diabetes Spectrum (American Diabetes Association)

Academic Journals

• The Journal of Clinical Endocrinology & Metabolism
• Diabetes Care
• The Lancet Diabetes & Endocrinology
• Diabetologia
• Journal of Diabetes Research
• Diabetes Research and Clinical Practice
• International Journal of Obesity

Reputable Newspapers

• The New York Times
• The Guardian
• The Washington Post
• Financial Times
• The Wall Street Journal
• Reuters
• Associated Press

Industry Associations

• American Diabetes Association (ADA)
• European Association for the Study of Diabetes (EASD)
• International Diabetes Federation (IDF)
• National Institute for Health and Care Excellence (NICE)
• American Association of Clinical Endocrinologists (AACE)
• Diabetes UK
• Canadian Diabetes Association

Public Domain Resources

• National Institutes of Health (NIH) Public Access Repository
• U.S. Food and Drug Administration (FDA) Database
• Centers for Disease Control and Prevention (CDC) Data
• World Health Organization (WHO) Global Health Observatory
• National Health Service (NHS) Digital

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years